α9-nicotinic acetylcholine receptors contribute to the maintenance of chronic mechanical hyperalgesia, but not thermal or mechanical allodynia

BACKGROUND: The current pharmacological treatments for chronic pain are limited. The first analgesic drug approved for clinical use in decades that has a novel molecular target is the synthetic version of a naturally occurring conotoxin. Several conotoxins that target ion channels have progressed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Mohammadi, Sarasa, Christie, Macdonald J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195954/
https://www.ncbi.nlm.nih.gov/pubmed/25274008
http://dx.doi.org/10.1186/1744-8069-10-64

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195954/
https://www.ncbi.nlm.nih.gov/pubmed/25274008
http://dx.doi.org/10.1186/1744-8069-10-64

Ejemplares similares